Table 1

Pain measures in AIM compared with the general population

Study	AIM subsets	Pain severity*		P value
Study	AIM subsets	AIM	General population	P value
SF-36 BP (additive 0–100, norm-based mean 50, SD 10); lower score, more pain
Sultan et al26	DM, PM, OM	Mean: 55	Mean: 90	<0.001
Ponyi et al28	DM, PM, OM	Mean±SD DM: 54±18 PM: 58±20 OM: 66±18	Mean: 78	<0.001
Sadjadi et al29	IBM	Mean±SD 69±27	Z-score: −0.2	Non-significant
van de Vlekkert et al35	DM, OM, NS, NAM	Mean: 42†	Mean: 80	<0.05
Goreshi et al23	DM	Norm-based Mean: 50	Norm-based Mean: 52	Non-significant
Regardt et al32	DM, PM	Mean: 58	Mean: 70	0.023
Xu et al43	DM, PM, IBM, NAM, NS	Mean±SD 63±26	Mean±SD 77±25	<0.001
Cleary et al21	DM, PM, OM, IBM	Median (IQR) 78 (45–95)	Median (IQR) General population: 95 (82–100)	0.08
Feldon et al22	DM, PM, IBM, adult JDM	Norm-based Mean±SE 43±0.28	Norm-based Mean±SE 49±0.21	<0.0001
Poulsen et al36	DM, PM	Mean±SD 60±26	Median (IQR) 100 (72–100)	<0.001
NHP score (0–100); higher score, more pain
Chung et al19	DM, PM	Mean±SD 30±32	Mean±SD RA: 49±34 OP: 33±36 OA: 41±27 General population: 6	N/A

*If not shown, measure of dispersion not provided.
†Baseline values at entry in the cohort.
AIM, autoimmune idiopathic myopathy; DM, dermatomyositis; IBM, inclusion body myositis; JDM, juvenile dermatomyositis; N/A, not available; NAM, necrotising autoimmune myopathy; NHP, Nottingham Health Profile; NS, non-specific; OA, osteoarthritis; OM, overlap myositis; OP, osteoporosis; PM, polymyositis; RA, rheumatoid arthritis; SF-36 BP, 36-Item Short Form Bodily Pain.